Abstract

Research Article

Audit of the effect of non-nasal specific scoring on the Postoperative SNOT22 questionnaire

Samir Gendy*

Published: 23 September, 2020 | Volume 4 - Issue 1 | Pages: 003-005

The Sino-nasal outcome test (SNOT22) has been widely adopted in clinical practice and has been declared as the most suitable sinonasal outcome scoring system. It is simple disease specific encompassing 22 symptoms reflecting health burden of the rhino- logical patients.

Each item quantifies symptoms severity from 0(no problem) to 5 (worst symptom). The sum of each item results in a maximum score of 110. High score indicates poor outcome.

Read Full Article HTML DOI: 10.29328/journal.ated.1001010 Cite this Article Read Full Article PDF

References

  1. Snidvongs K, Heller GZ, Harvey RJ. Validity of European Position Paper on Rhino sinusitis disease control assessment and modification in Chronic Rhino sinusitis.Otolaryng. Head Neck Surg. 2014; 150: 479-486. PubMed: https://pubmed.ncbi.nlm.nih.gov/24343022/
  2. Kordjian HH. Sixty-Three patient-based survey-Can SNOT-22 test be a suitable evaluation method for septoplasty and turbinectomy Clin.Otolaryng. 2017; 42: 1373-1377
  3. Zachary M, Jones R, le P, Rudmik L, Mattos JL, et al. SNOT-22 outcomes after sinus surgery a systematic review and meta-analysis. Laryngoscope. 2018; 128: 581-592. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814358/
  4. Kennedy J, Hubbard M, Huyett P, Patrie JT, Borish L, et al. SNOT-22: A predictor of post-surgical improvement in patients with chronic sinusitis. Ann Allergy Asthma Immunol.2013; 111: 246-251. PubMed: https://pubmed.ncbi.nlm.nih.gov/24054358/

Figures:

Figure 1

Figure 1

Similar Articles

Recently Viewed

  • Analysis of the Factors of Therapeutic Failure after Transition to Acriptega: About Two Cases
    Medard Amona*, Yolande Voumbo Mavoungou Matoumona, Hama Nemet Ondzotto, Grace Paterson Ngouaka, Benjamin Kokolo, Armel Itoua, Gilius Axel Aloumba and Pascal Ibata Medard Amona*,Yolande Voumbo Mavoungou Matoumona,Hama Nemet Ondzotto,Grace Paterson Ngouaka,Benjamin Kokolo,Armel Itoua,Gilius Axel Aloumba,Pascal Ibata. Analysis of the Factors of Therapeutic Failure after Transition to Acriptega: About Two Cases. Int J Clin Microbiol Biochem Technol. 2026: doi: 10.29328/journal.ijcmbt.1001033; 9: 001-009
  • Global Burden and Future Outlook of Antimicrobial Resistance
    Muhammad Ajmal Dina*, Muhammad Akram Bhutta and Syed Ahmed Zeshan Muhammad Ajmal Dina*,Muhammad Akram Bhutta,Syed Ahmed Zeshan. Global Burden and Future Outlook of Antimicrobial Resistance. Int J Clin Microbiol Biochem Technol. 2026: doi: 10.29328/journal.ijcmbt.1001035; 9: 018-021
  • Adult Bladder Exstrophy with Premalignant Changes Following Failed Reconstruction: A Case Report
    Mohammed Amine Elafari*, Mamad Ayoub, Mohamed Amine Zaki, Mohammed Amine Bibat, Amine Slaoui, Tarik Karmouni, Abdelatif Koutani and Khalid Elkhader Mohammed Amine Elafari*,Mamad Ayoub,Mohamed Amine Zaki,Mohammed Amine Bibat,Amine Slaoui,Tarik Karmouni,Abdelatif Koutani,Khalid Elkhader. Adult Bladder Exstrophy with Premalignant Changes Following Failed Reconstruction: A Case Report. J Clin Med Exp Images. 2026: doi: 10.29328/journal.jcmei.1001044; 10: 020-023
  • Late Extensive Regional Recurrence of Paratesticular Dedifferentiated Liposarcoma 10 Years after Orchiectomy: A Case Report
    Mohammed Amine Elafari*, Mamad Ayoub, Mohammed Amine Bibat, Amine Slaoui, Tariq Karmouni, Abdelatif Koutani and Khalid Elkhader Mohammed Amine Elafari*,Mamad Ayoub,Mohammed Amine Bibat,Amine Slaoui,Tariq Karmouni,Abdelatif Koutani,Khalid Elkhader. Late Extensive Regional Recurrence of Paratesticular Dedifferentiated Liposarcoma 10 Years after Orchiectomy: A Case Report. Arch Cancer Sci Ther. 2026: doi: 10.29328/journal.acst.1001049; 10: 006-010
  • The Police Power of the National Health Surveillance Agency – ANVISA
    Dimas Augusto da Silva* and Rafaela Marinho da Silva Dimas Augusto da Silva*,Rafaela Marinho da Silva. The Police Power of the National Health Surveillance Agency – ANVISA. Arch Cancer Sci Ther. 2024: doi: 10.29328/journal.acst.1001046; 8: 063-076

Read More

Most Viewed

Read More

Help ?